Effect of Sacubitril-Valsartan Combined with Zhenyuan Capsule in the Treatment of Chronic Heart Failure Comorbid Anxiety and Depression and Its Effect on Inflammatory Factors
- 1 Department of Cardiology, Nanning Third People’s Hospital, Nanning, China
- 2 Department of Cardiology, Nanning Third People’s Hospital, Nanning, China
- 3 Department of Cardiology, Nanning Third People’s Hospital, Nanning, China
- 4 Department of Cardiology, Nanning Third People’s Hospital, Nanning, China
- 5 Department of Cardiology, Nanning Third People’s Hospital, Nanning, China
- 6 Department of Cardiology, Nanning Third People’s Hospital, Nanning, China
- 7 Department of Cardiology, Nanning Third People’s Hospital, Nanning, China
Abstract
Objective: To investigate the effect of sacubitril-valsartan combined with Zhenyuan capsule in the treatment of chronic heart failure comorbid anxiety and depression and its effect on the level of inflammatory factors. Methods: A total of 106 patients with chronic heart failure comorbid anxiety and depression from February 2020 to March 2022 were continuously enrolled and divided into control group (36 cases), observation group A (36 cases) and observation group B (34 cases) according to treatment methods. All groups were given conventional treatment. On the basis of routine treatment, the control group, observation group A and observation group B were given valsartan, sacubitril-valsartan and sacubitril-valsartan plus Zhenyuan Capsules for the treatment of consecutive 8 weeks. The patients in the 3 groups were evaluated by the Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) before and after treatment, and the clinical efficacy of heart failure was evaluated, and the detection of left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), N terminal brain natriuretic peptide (NT-proBNP), tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL-6), c-reactive protein (CRP) was conducted. Results: The clinical efficacy rate and total effective rate of heart failure in observation group A and observation group B were significantly higher than those in the control group (P < 0.05), and the observation group B was higher than the observation group A (P < 0.05); SAS and SDS scores in observation group A and observation group B were significantly lower than the control group (P < 0.05), and observation group B was lower than observation group A (P < 0.05); The LVEF in the three groups was all increased compared with those before treatment, and the levels of LVESD, LVEDD, NT-proBNP, TNF-α, IL-6, and hs-CRP were all decreased compared with those before treatment; The changes of above indexes in observation group A and observation group B were more significant than those in control group (P < 0.05). Except for the LVEDD index, the observation group B had significant changes compared with the observation group A (P < 0.05). Conclusion: Sacubitril valsartan can improve cardiac function, reduce inflammatory response, and improve anxiety and depression in patients with chronic heart failure, and the treatment effect of combination with Zhenyuan Capsule is more significant.
- Rosamond, W., Flegal, K., Friday, G., Furie, K., Go, A., Greenlund, K., et al. (2007) Heart Disease and Stroke Statistics—2007 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 115, e69-e171. https://doi.org/10.1161/CIRCULATIONAHA.106.179918
- Li, G., Zhu, Y., Han, N., Cao, C.L. and Li, Z.Z. (2015) Effects of Linggui Zhugan Decoction on Cardiac Function in Patients with Chronic Heart Failure. Journal of Clinical Psychosomatic Diseases, 21, 27-28.
- Lise, T.G., Lars, E.L., Imre, J., Dalen, H. and Bjerkeset, O. (2014) Symptoms of Anxiety and Depression and Risk of Heart Failure: The HUNT Study. European Journal of Heart Failure, 16, 861-870. https://doi.org/10.1002/ejhf.133
- Sinnamon, A.J.T., Tong, J.K.C., Bailey, E.A., Brown, C., Colbert, L., Murray, S., et al. (2018) Prospective Implementation of a Standardized Screening Protocol for Deep Venous Thrombosis in Abdominal Surgical Oncology Patients. Journal of Surgical Oncology, 118, 568-573. https://doi.org/10.1002/jso.25151
- Brouwers, C., Christensen, S.B., Damen, N.L., Denollet, J., Torp-Pedersen, C., Gislason, G.H., et al. (2016) Antidepressant Use and Risk for Mortality in 121, 252 Heart Failure Patients with or without a Diagnosis of Clinical Depression. International Journal of Cardiology, 203, 867-873. https://doi.org/10.1016/j.ijcard.2015.11.032
- Rutledge, T., Reis, V.A., Linke, S.E., Greenberg, B.H. and Mills, P.J. (2006) Depression in Heart Failure a Meta-Analytic Review of Prevalence, Intervention Effects, and Associations with Clinical Outcomes. Journal of the American College of Cardiology, 48, 1527-1537. https://doi.org/10.1016/j.jacc.2006.06.055
- Zhang, J., Liu, P., Lyu, R., et al. (2008) A Preliminary Study Comparing Different Scales to Evaluate Anxiety/depression in Patients with Heart Failure and Non-Heart Failure. Chinese Journal of Circulation, 23, 120-122.
- Chen, L., Liu, J., Zhang, J., et al. (2017) Research on Cognitive Emotion Regulation, Quality of Life and Anxiety and Depression in Patients with Chronic Heart Failure. China Circulation Journal, 32, 956-959.
- Shi, X., Kang, Y., Chen, C., et al. (2017) Study on the Comorbidity of Anxiety and Depression and Its Related Factors in Hospitalized Patients with Heart Failure. Journal of Sichuan University (Medical Edition), 48, 435-440.
- Zhang, Y. and Lu, J. (2014) Effects of Anti-Anxiety and Depression Therapy on the Quality of Life of Patients with Chronic Heart Failure Complicated with Anxiety and Depression. Chinese Medicine Guidelines, 12, 62-63.